Should I buy or sell AbbVie stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares. View ABBV analyst ratings or view top-rated stocks .

What is AbbVie's stock price target for 2024?

14 analysts have issued 12-month target prices for AbbVie's stock. Their ABBV share price targets range from $150.00 to $200.00. On average, they anticipate the company's share price to reach $179.64 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts .

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 at the beginning of the year. Since then, ABBV shares have increased by 10.6% and is now trading at $171.35. View the best growth stocks for 2024 here .

Are investors shorting AbbVie?

AbbVie saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 15,930,000 shares, an increase of 10.0% from the April 30th total of 14,480,000 shares. Based on an average daily trading volume, of 5,580,000 shares, the short-interest ratio is currently 2.9 days. Currently, 0.9% of the shares of the company are short sold. View AbbVie's Short Interest .

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our ABBV earnings forecast .

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Friday, May, 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.05. The business had revenue of $12.31 billion for the quarter, compared to analyst estimates of $11.93 billion. AbbVie had a net margin of 11.02% and a trailing twelve-month return on equity of 179.47%. The firm's quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share. Read the conference call transcript .

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 15th. Stockholders of record on Monday, April 15th will be paid a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 annualized dividend and a dividend yield of 3.62%. The ex-dividend date of this dividend is Friday, April 12th. Read our dividend analysis for ABBV .

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.68%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 183.98%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 51.32% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ABBV .

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include Harbor Health Care ETF (MEDI) , First Trust Morningstar Dividend Leaders Index (FDL) , Horizon Kinetics Medical ETF (MEDX) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Invesco Pharmaceuticals ETF (PJP) , VanEck Pharmaceutical ETF (PPH) , WisdomTree U.S. High Dividend Fund (DHS) and Health Care Select Sector SPDR Fund (XLV) .

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its second quarter 2024 earnings guidance on Friday, April, 26th. The company provided EPS guidance of 3.050-3.090 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $14.0 billion-$14.0 billion, compared to the consensus revenue estimate of $13.6 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com . Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC) , Constellation Software (CSU) , AutoCanada (ACQ) , Alimentation Couche-Tard (ATD.B) , Vermilion Energy (VET) , AT&T (T) , Bristol-Myers Squibb (BMY) , Wheaton Precious Metals (WPM) , Rogers Communications (RCI) and Open Text (OTEX) .

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.65%), Capital International Investors (2.72%), Capital Research Global Investors (1.77%), Bank of New York Mellon Corp (1.12%), Janus Henderson Group PLC (0.62%) and Price T Rowe Associates Inc. MD (0.61%). Insiders that own company stock include Azita Saleki-Gerhardt , Brian L Durkin , Carrie C Strom, Carrie C Strom , Elaine K Sorg , Henry O Gosebruch , Jeffrey Ryan Stewart , Kevin K Buckbee , Laura J Schumacher , Michael Severino , Nicholas Donoghoe , Perry C Siatis , Richard A Gonzalez , Robert A Michael , Roxanne S Austin , Scott T Reents and Timothy J Richmond . View institutional ownership trends .

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. Read More

Top-Rated StocksTop-Rated Top-Rated Dividend StocksTop-Rated Dividend

NYSE:ABBV

AbbVie (ABBV) Stock Price, News & Analysis

→ [Urgent] Protect your money before November (From Weiss Ratings) (Ad)

Free ABBV Stock Alerts

$171.35

+1.67 (+0.98%)

(As of 06/18/2024 ET)

Compare

Today's Range: $169.87
▼
$173.00
50-Day Range: $154.86
▼
$171.35
52-Week Range: $130.96
▼
$182.89

Volume: 4.25 million shs
Average Volume: 5.46 million shs
Market Capitalization: $302.58 billion

P/E Ratio: 50.85
Dividend Yield: 3.62%
Price Target: $179.64

Get AbbVie alerts:

AbbVie MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 4.8% Upside
$179.64 Price Target
Short Interest: Healthy
0.94% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.34
Upright™ Environmental Score
News Sentiment: 0.69
Based on 25 Articles This Week
Insider Trading: Selling Shares
$3.72 M Sold Last Quarter
Proj. Earnings Growth: 7.28%
From $11.26 to $12.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Medical Sector

61st out of 913 stocks

Pharmaceutical Preparations Industry

23rd out of 430 stocks

2.4

Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
AbbVie has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about AbbVie's stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
0.94% of the float of AbbVie has been sold short.
Short Interest Ratio / Days to Cover
AbbVie has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AbbVie has recently increased by 3.52%, indicating that investor sentiment is decreasing.

4.2

Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 3.68%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 52 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 183.98%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 51.32% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
Read more about AbbVie's dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AbbVie has received a 52.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Adalimumab", "Ibrutinib", and "Hepatitis medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AbbVie is -2.34.

2.1

News and Social Media Coverage

News Sentiment
AbbVie has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 25 news articles for AbbVie this week, compared to 24 articles on an average week.
Search Interest
Only 124 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
MarketBeat Follows
Only 71 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -34% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,716,757.00 in company stock.
Percentage Held by Insiders
Only 0.25% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about AbbVie's insider trading history.

2.5

Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to grow by 7.28% in the coming year, from $11.26 to $12.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 50.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 50.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 158.42.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AbbVie has a P/B Ratio of 29.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about AbbVie's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

[Urgent] Protect your money before November

Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.

Click here to watch now.

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

Written by Jeffrey Neal Johnson

ABBV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABBV Stock News Headlines

June 6, 2024 | marketbeat.com

Investing in Biotech: High Risk for a Potentially High Reward

Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit.

May 31, 2024 | marketbeat.com

2 Generic Drug Makers With Growing Runways (ABBV)

Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.

June 19, 2024 | Weiss Ratings (Ad)

[Urgent] Protect your money before November

June 19 at 4:19 AM | fool.com

2 Super Smart Dividend Stocks to Buy With $10,000 Right Now

June 18 at 9:04 PM | marketwatch.com

AbbVie says FDA approves Skyrizi for ulcerative colitis

June 18 at 9:03 PM | seekingalpha.com

AbbVie: 5 Reasons That Make A Buy Case

June 18 at 6:18 PM | prnewswire.com

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

June 18 at 12:00 PM | americanbankingnews.com

AbbVie (NYSE:ABBV) PT Raised to $190.00

June 19, 2024 | Weiss Ratings (Ad)

[Urgent] Protect your money before November

June 16 at 8:30 AM | fool.com

2 Dividend Stocks That Could Pay You for Life

June 16 at 3:52 AM | americanbankingnews.com

AbbVie (NYSE:ABBV) Shares Up 0.8%

June 14, 2024 | prnewswire.com

AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer

June 14, 2024 | investorplace.com

The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks

June 13, 2024 | reuters.com

AbbVie inks immune disorder drug licensing deal with China's FutureGen

June 13, 2024 | prnewswire.com

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

June 12, 2024 | seekingalpha.com

AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

June 12, 2024 | investorplace.com

Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts

June 12, 2024 | globenewswire.com

US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch

June 11, 2024 | prnewswire.com

BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients

June 7, 2024 | reuters.com

Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars

June 6, 2024 | insidermonkey.com

Is AbbVie Inc. (NYSE:ABBV) the Most Undervalued Dividend Aristocrat Stock According to Analysts?

June 6, 2024 | prnewswire.com

AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer

June 6, 2024 | prnewswire.com

SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

June 6, 2024 | prnewswire.com

AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

June 6, 2024 | investorplace.com

Hedge Fund Favorites: 7 Stocks to Buy When You're Feeling Jittery

June 5, 2024 | investorplace.com

Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential

June 5, 2024 | fool.com

2 High-Yield Dividend Stocks to Buy Right Now

See More Headlines

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/15 Dividend: 4/12/2024
Last Earnings: 5/03/2024
Dividend Payable: 5/15/2024
Today: 6/18/2024
Next Earnings (Estimated): 7/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ABBV
CUSIP: 00287Y10
CIK: 1551152
Web: www.abbvie.com
Phone: (847) 932-7900
Fax: 302-655-5049
Employees: 50,000
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $179.64
High Stock Price Target: $200.00
Low Stock Price Target: $150.00
Potential Upside/Downside: +4.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.37
Trailing P/E Ratio: 50.85
Forward P/E Ratio: 15.22
P/E Growth: 2.16
Net Income: $4.86 billion
Net Margins: 11.02%
Pretax Margin: 13.84%
Return on Equity: 179.47%
Return on Assets: 14.05%

Debt

Debt-to-Equity Ratio: 7.93
Current Ratio: 0.94
Quick Ratio: 0.83

Sales & Book Value

Annual Sales: $54.32 billion
Price / Sales: 5.57
Cash Flow: $16.07 per share
Price / Cash Flow: 10.66
Book Value: $5.78 per share
Price / Book: 29.65

Miscellaneous

Outstanding Shares: 1,765,870,000
Free Float: 1,761,453,000
Market Cap: $302.58 billion
Optionable: Optionable
Beta: 0.60

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Richard A. Gonzalez (Age 70)
Chairman & CEO
Comp: $7.19M
Mr. Robert A. Michael (Age 54)
President & COO
Comp: $4.62M
Mr. Scott T. Reents (Age 56)
Executive VP & CFO
Comp: $3.13M
Dr. Azita Saleki-Gerhardt Ph.D. (Age 61)
Executive VP & COO
Comp: $3.51M
Mr. Jeffrey Ryan Stewart (Age 55)
Executive VP & Chief Commercial Officer
Comp: $4.32M
Dr. Thomas J. Hudson M.D. (Age 62)
Senior VP & Chief Scientific Officer of Global Research
Ms. Elizabeth Shea
Senior Vice President of Investor Relations
Mr. Perry C. Siatis (Age 49)
Executive VP, General Counsel & Secretary
Mr. Sanjay Narayan
Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Timothy J. Richmond (Age 58)
Executive VP & Chief Human Resources Officer
Comp: $1.12M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie's flagship brand, Humira, has shown record-breaking performance under Elaine Sorg's leadership, with consistent sales growth exceeding $1 billion annually.
Recent successful launches of Venclexta for Relapsed Refractory CLL and AML, and Skyrizi for plaque psoriasis, have exceeded market expectations, indicating strong growth potential.
Rinvoq, in the early stages of launch for rheumatoid arthritis treatment, presents a promising opportunity for revenue growth in the pharmaceutical market.
AbbVie's Patient Services organization, particularly the HUMIRA Complete program, is recognized as the best in the industry, enhancing patient support and loyalty.
Elaine Sorg's extensive experience and leadership in the biopharmaceutical industry, coupled with her track record of successful product launches, instills confidence in AbbVie's future growth prospects.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

Market volatility and regulatory challenges in the pharmaceutical industry can impact AbbVie's stock price, leading to potential short-term fluctuations.
Competition from other pharmaceutical companies in the immunology and oncology sectors may pose challenges to AbbVie's market share and revenue growth.
Dependency on the success of key products like Humira, Venclexta, and Skyrizi for revenue generation exposes AbbVie to risks associated with product lifecycle and patent expirations.
Global economic conditions and healthcare policy changes can influence demand for AbbVie's products, affecting sales and profitability.
Investors should carefully monitor AbbVie's financial performance, pipeline developments, and regulatory updates to make informed investment decisions.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.
What is AbbVie's stock price target for 2024?: 14 analysts have issued 12-month target prices for AbbVie's stock. Their ABBV share price targets range from $150.00 to $200.00. On average, they anticipate the company's share price to reach $179.64 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.
How have ABBV shares performed in 2024?: AbbVie's stock was trading at $154.97 at the beginning of the year. Since then, ABBV shares have increased by 10.6% and is now trading at $171.35.
View the best growth stocks for 2024 here.
Are investors shorting AbbVie?: AbbVie saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 15,930,000 shares, an increase of 10.0% from the April 30th total of 14,480,000 shares. Based on an average daily trading volume, of 5,580,000 shares, the short-interest ratio is currently 2.9 days. Currently, 0.9% of the shares of the company are short sold.
View AbbVie's Short Interest.
When is AbbVie's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our ABBV earnings forecast.
How were AbbVie's earnings last quarter?: AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Friday, May, 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.05. The business had revenue of $12.31 billion for the quarter, compared to analyst estimates of $11.93 billion. AbbVie had a net margin of 11.02% and a trailing twelve-month return on equity of 179.47%. The firm's quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share.
Read the conference call transcript.
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?: AbbVie announced a quarterly dividend on Thursday, February 15th. Stockholders of record on Monday, April 15th will be paid a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 annualized dividend and a dividend yield of 3.62%. The ex-dividend date of this dividend is Friday, April 12th.
Read our dividend analysis for ABBV.
Is AbbVie a good dividend stock?: AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.68%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 183.98%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 51.32% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What ETFs hold AbbVie's stock?: ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include Harbor Health Care ETF (MEDI), First Trust Morningstar Dividend Leaders Index (FDL), Horizon Kinetics Medical ETF (MEDX), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Pharmaceuticals ETF (PJP), VanEck Pharmaceutical ETF (PPH), WisdomTree U.S. High Dividend Fund (DHS) and Health Care Select Sector SPDR Fund (XLV).
What guidance has AbbVie issued on next quarter's earnings?: AbbVie updated its second quarter 2024 earnings guidance on Friday, April, 26th. The company provided EPS guidance of 3.050-3.090 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $14.0 billion-$14.0 billion, compared to the consensus revenue estimate of $13.6 billion.
What is Richard A. Gonzalez's approval rating as AbbVie's CEO?: 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.
What other stocks do shareholders of AbbVie own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).
Who are AbbVie's major shareholders?: AbbVie's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.65%), Capital International Investors (2.72%), Capital Research Global Investors (1.77%), Bank of New York Mellon Corp (1.12%), Janus Henderson Group PLC (0.62%) and Price T Rowe Associates Inc. MD (0.61%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Kevin K Buckbee, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.
How do I buy shares of AbbVie?: Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does AbbVie have any subsidiaries?: The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More

This page (NYSE:ABBV) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Leadership

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio

About AbbVie Stock (NYSE:ABBV)

ABBV Stock Price History

ABBV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Cons

ABBV Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™